De Novo Stenosis Clinical Trial
— REC-CHIPCACOfficial title:
Intravascular Lithotripsy Versus Conventional Therapy for Severely Calcified Coronary Artery Lesions: an Investigator-initiated, Open-label, Multicentre, Randomised, Superiority Trial
Percutaneous coronary intervention (PCI) encounters challenges with calcified coronary lesions, leading to potential issues such as failed balloon dilatation, incomplete stent expansion, and increased risks of adverse events post-PCI, including stent restenosis and thrombosis. Intravascular lithotripsy (IVL), a novel approach for severely calcified coronary lesion preparation, has shown promising preliminary outcomes. Combining IVL with conventional approaches, such as Rotational atherectomy (RA), non-compliant balloons, or cutting balloons, may associated with additional benefit than conventional approaches only in terms of better stent expansion and lower long-term adverse events. This pilot randomized trial aims to investigate whether combining IVL to conventional therapy surpasses the efficacy of conventional approaches alone. The primary effectiveness endpoint is final stent expansion assessed by post-procedure optical coherence tomography (OCT), and the primary safety endpoint is target lesion failure (TVF). The trial seeks to provide valuable insights into the optimal approach for managing severely calcified coronary lesions during PCI.
Status | Recruiting |
Enrollment | 220 |
Est. completion date | March 1, 2025 |
Est. primary completion date | December 1, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: General Inclusion Criteria: 1. Patients with acute or chronic coronary artery syndrome indicated for PCI with stenting. 2. Able to understand and provide informed consent and comply with all study procedures Angiographic Inclusion Criteria: 1. Native and de novo coronary artery disease 2. Lesion navigable by a 0.014" guidewire. 3. Target lesion is severely calcified, meeting one of the following criteria: - Presence of calcium = 270°, lengths = 5mm, and thickness = 0.5mm at one cross-section as assessed by OCT - If the OCT catheter is unable to pass through the target lesion after dilatation due to calcification or tortuosity, and the target lesion is severely calcified on both sides of the arterial wall during angiography, with the length of the calcification >15 mm, the lesion will be recognized as a severely calcified lesion, meeting the criteria for enrollment Exclusion Criteria: General Exclusion Criteria: 1. Patients under 18 years of age. 2. Incapable of providing informed consent. 3. Female patients who are pregnant or nursing (a pregnancy test must be conducted within 7 days before the index procedure for women of childbearing potential, as per local practice). 4. Concurrent medical conditions with a life expectancy of less than 1 year. 5. Hemodynamic instability. 6. Known contraindications to medications such as Heparin, anticoagulation, antiplatelet drugs, or contrast. 7. Active bleeding. 8. New-onset stroke or transient ischemic attack (TIA) within 90 days prior to enrollment. 9. Severe renal dysfunction (eGFR = 30 ml/min). 10. Patients scheduled to undergo cardiac intervention or cardiac surgery within 30 days of the index procedure. 11. Recent ST-segment elevation myocardial infarction (STEMI) within 7 days or recent cardiogenic shock. 12. Lesions located in surgical conduits. Angiographic Exclusion Criteria: 1. Target vessel exhibiting C-F type dissection. 2. Thrombosis observed by angiography or OCT. 3. Presence of an aneurysm within 10 mm of the target lesion. 4. Left main ostial lesion |
Country | Name | City | State |
---|---|---|---|
China | Ling Tao | Xi'an | Shannxi |
Lead Sponsor | Collaborator |
---|---|
Xijing Hospital |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Suboptimal stent deployment | Suboptimal stent deployment is defined as fulfilling any of the following criteria: minimum stent area (MSA) =4.5mm2 (by OCT), MSA/mean reference lumen area =80%, flow-limiting dissections, or incomplete stent apposition (axial distance =0.4 mm and length =1 mm) | Measured by the data collected at the end of the PCI procedure | |
Other | Stent delivery failure | Measured by the data collected at the end of the PCI procedure | ||
Other | Cardiac cause death | 1, 12, 36, and 60 months | ||
Other | Target vessel myocardial infarction (TV-MI) | 1, 12, 36, and 60 months | ||
Other | Clinically indicated target lesion revascularization (CI-TLR) | 1, 12, 36, and 60 months | ||
Other | Clinically indicated target vessel revascularization (CI-TVR) | 1, 12, 36, and 60 months | ||
Other | All cause death | 1, 12, 36, and 60 months | ||
Other | Any stroke | 1, 12, 36, and 60 months | ||
Other | Any MI | 1, 12, 36, and 60 months | ||
Other | Any revascularisation | 1, 12, 36, and 60 months | ||
Other | Patient-oriented composite endpoint (PoCE) | Patient-oriented composite endpoint (PoCE) is defined as all-cause death, any stroke, any MI, and any clinically indicated revascularisation | 1, 12, 36, and 60 months | |
Other | Definite/Probable Stent thrombosis rates | According to ARC-II classification | 1, 12, 36, and 60 months | |
Other | Peri-procedural MI | According to SCAI definition | 48 hours | |
Other | Peri-procedural major adverse events | Peri-procedural major adverse events were defined as a composite of the procedure of periprocedural MI, flow-limiting dissections, perforation/rupture, acute occlusion, slow-flow/no-reflow, ventricular tachycardia/ventricular fibrillation within 30 days | 30 days | |
Other | Acute gain | Acute gain is the difference between post- and pre-procedural minimal lumen diameter (MLD) as measured in (preferable) identical orthogonal views by OCT (MLDpost - MLDpre) | Measured by the data collected at the end of the PCI procedure | |
Other | The difference between post- and pre-procedural FFR/IMR | FFR/IMR can be measured either by wire or derived from coronary angiography | Measured by the data collected at the end of the PCI procedure | |
Other | Procedure time of the PCI | Measured by the data collected at the end of the PCI procedure | ||
Other | Radiation dose of the PCI | Measured by the data collected at the end of the PCI procedure | ||
Other | Contrast volume | Measured by the data collected at the end of the PCI procedure | ||
Other | Calcium fracture | Measured by the data collected at the end of the PCI procedure | ||
Other | Angiographic success | Angiographic success is defined as the ability of the allocated treatment to produce residual stenosis <20% after stenting without serious angiographic complications (severe dissection impairing flow [type D-F], perforation, abrupt closure, persistent slow flow, or no-reflow). | Measured by the data collected at the end of the PCI procedure | |
Other | Strategy success | Strategy success is defined as Angiographic success without treatment crossover or stent loss | Measured by the data collected at the end of the PCI procedure | |
Other | Clinical (Procedural) success | Clinical (Procedural) success is defined as Device success without the occurrence of in-hospital cardiovascular death, target-vessel myocardial infarction, or clinically indicated target vessel revascularization. | 1 month | |
Other | Coronary flow velocity | Coronary flow velocity is measured by Quantitative Flow Ratio (QFR) | Measured by the data collected at the end of the PCI procedure | |
Other | TIMI Flow | Measured by the data collected at the end of the PCI procedure | ||
Other | Stent malapposition | Measured by the data collected at the end of the PCI procedure | ||
Other | Stent volume / reference lumen volume | Assessed by OCT | Measured by the data collected at the end of the PCI procedure | |
Other | Mean stent area / Mean reference lumen area | Assessed by OCT Assessed by OCT | Measured by the data collected at the end of the PCI procedure | |
Primary | Final stent expansion (%) assessed by OCT | The primary efficacy endpoint of the trial is the Final stent expansion %, defined as the minimum stent area (MSA) / mean reference lumen area assessed by OCT. | Measured by the data collected at the end of the PCI procedure | |
Primary | Target vessel failure (TVF) | The primary safety endpoint of the trial is target vessel failure (TVF), defined as a non-hierarchical composite endpoint of cardiovascular death, target-vessel myocardial infarction (TV-MI), and clinically indicated target vessel revascularization (CI-TVR). | 1, 12, 36, and 60 months | |
Secondary | Major cardiovascular adverse events | Major adverse cardiovascular events (MACE) is defined as a hierarchical composite of cardiovascular death, target-vessel myocardial infarction, clinically indicated target vessel revascularization, stent delivery failure, and suboptimal stent deployment.
The between-group difference in terms of MACE will be compared using the Win Ratio approach in the abovementioned order. |
1, 12, 36, and 60 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05846893 -
Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease
|
N/A | |
Recruiting |
NCT06084000 -
STrategies of Scheduled Drug-coated Balloons (DCB) Versus Conventional DES for the interveNTional Therapy of de Novo Lesions in Large Coronary vESSels (STENTLESS) Trial
|
N/A | |
Recruiting |
NCT05438121 -
STabilization of Atheroma By Lipid-reducing Effect of Drug-Coated Balloon (STABLE-DCB)
|
||
Recruiting |
NCT06247982 -
Bail-Out Stenting and Target-vessel Failure After Drug Coated Balloon Coronary percutaneouS Angioplasty for de Novo Lesions
|
||
Completed |
NCT05134545 -
Compare the Efficacy and Safety of Genoss® DCB and IN.PACT Admiral® DCB in Patients With Peripheral Artery Disease
|
N/A | |
Completed |
NCT04234893 -
Bingo Drug-Coated Balloon in Real World
|
||
Active, not recruiting |
NCT05209412 -
Paclitaxel-Coated Balloon Versus Zotarolimus-Eluting Stent for Treatment of De Novo Coronary Artery Lesions
|
N/A | |
Active, not recruiting |
NCT04561739 -
Paclitaxel-coated Balloon for Treatment of De-novo Non-complex Coronary Artery Lesions
|
N/A | |
Recruiting |
NCT05516446 -
Drug Eluting Balloon Angioplasty Versus Everolimus Platinum Chrome Stent
|
N/A | |
Recruiting |
NCT06013007 -
Joint Inflation With Nominal-pressure and Stability Approach in DES Optimization
|
N/A | |
Active, not recruiting |
NCT04937803 -
Safety and Efficacy of Drug-Coated Balloon for De-novo Lesions in Patients With Acute Coronary Syndromes (DCB-ACS)
|
N/A |